Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1275-1283

  Gao, Wei ^a   McCormick, Jennifer ^a   Connolly, Mary ^a   Balogh, Emese ^a   Veale, Douglas J ^a   Fearon, Ursula ^a   Kvien, Tore K ^b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; NOTCH1 RECEPTOR; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; STROMELYSIN; HIF1A PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL HYPOXIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; EX VIVO STUDY; EXPLANT; FEMALE; FIBROBLAST; GENE; HRT 1 GENE; HRT 2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM; ANOXIA; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; WESTERN BLOTTING;

ADULT; AGED; ANOXIA; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE;

EID: 84934985384     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204105     Document Type: Article

References (56)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-19.
2. Muller-Ladner U, Gay RE, Gay S. Molecular biology of cartilage and bone destruction. Curr Opin Rheumatol 1998; 10:212-19.
3. Akhavani MA, Madden L, Buysschaert I., et al. Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis. Arthritis Res Ther 2009; 11:R64.
4. Oliver KM, Garvey JF, Ng C.T., et al. Hypoxia activates NF-kappaB-dependent gene expression through the canonical signaling pathway. Antioxid Redox Signal 2009; 11:2057-64.
5. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-8.
6. Kennedy A, Ng CT, Biniecka M, et al. Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 2010; 62:711-21.
7. Ng CT, Biniecka M, Kennedy A., et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 2010; 69:1389-95.
8. Sivakumar B, Akhavani MA, Winlove C.P., et al. Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg Am 2008; 33:49-58.
9. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995; 64:621-51.
10. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-21.
11. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19:6613-26.
12. Turkson J, Bowman T, Garcia R., et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18:2545-52.
13. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008; 28:185-200.
14. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med 2009; 9:626-33.
15. Sestito R, Madonna S, Scarponi C., et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J 2011; 25:916-27.
16. Greenhill CJ, Rose-John S, Lissilaa R., et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2011; 186:1199-208.
17. Ju JH, Heo YJ, Cho M.L., et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum 2012; 64:3543-52.
18. Krause A, Scaletta N, Ji J.D., et al. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002; 169:6610-16.
19. Mori T, Miyamoto T, Yoshida H., et al. IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011; 23:701-12.
20. Kok SH, Hong CY, Kuo M.Y., et al. Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Arthritis Rheum 2009; 60:1451-62.
21. Rosengren S, Corr M, Firestein G.S., et al. The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71:440-7.
22. Coombs JH, Bloom BJ, Breedveld F.C., et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690, 550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010; 69:413-16.
23. Tanaka Y, Suzuki M, Nakamura H., et al. Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63:1150-8.
24. Oh MK, Park HJ, Kim N.H., et al. Hypoxia-inducible factor-1alpha enhances haptoglobin gene expression by improving binding of STAT3 to the promoter. J Biol Chem 2011; 286:8857-65.
25. Jung JE, Kim HS, Lee C.S., et al. STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med 2008; 40:479-85.
26. Jung JE, Lee HG, Cho I.H., et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005; 19:1296-8.
27. Lee JH, Suk J, Park J., et al. Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. Mol Cancer Res 2009; 7:1663-71.
28. Gao W, Sweeney C, Connolly M., et al. Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2012; 64:2104-13.
29. Gustafsson MV, Zheng X, Pereira T., et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9:617-28.
30. Fearon U, Mullan R, Markham T., et al. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 2006; 54:3152-62.
31. Ultaigh SN, Saber TP, McCormick J, et al. Blockade of Toll-like receptor 2 prevents spontaneous cytokine release from rheumatoid arthritis ex vivo synovial explant cultures. Arthritis Res Ther 2011; 13:R33.
32. Haas C, Aicher WK, Dinkel A, et al. Characterization of SV40T antigen immortalized human synovial fibroblasts: maintained expression patterns of EGR-1, HLA-DR and some surface receptors. Rheumatol Int 1997; 16:241-7.
33. Mix KS, McMahon K, McMorrow J.P., et al. Orphan nuclear receptor NR4A2 induces synoviocyte proliferation, invasion, and matrix metalloproteinase 13 transcription. Arthritis Rheum 2012; 64:2126-36.
34. Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011; 13:R68.
35. Sawa S, Kamimura D, Jin G.H., et al. Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells. J Exp Med 2006; 203:1459-70.
36. Iwamaru A, Szymanski S, Iwado E., et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26:2435-44.
37. Kong LY, Wei J, Sharma A.K., et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 2009; 58:1023-32.
38. Ferrajoli A, Faderl S, Van Q., et al. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 2007; 67:11291-9.
39. Horiguchi A, Asano T, Kuroda K., et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 2010; 102:1592-9.
40. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67:9630-6.
41. Verstovsek S, Manshouri T, Quintas-Cardama A, et al. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 2008; 14:788-96.
42. Wang GS, Qian GS, Zhou D.S., et al. JAK-STAT signaling pathway in pulmonary arterial smooth muscle cells is activated by hypoxia. Cell Biol Int 2005; 29: 598-603.
43. Demyanets S, Kaun C, Rychli K., et al. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-gamma. Basic Res Cardiol 2011; 106:217-31.
44. Bill MA, Fuchs JR, Li C, et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer 2010; 9:165.
45. Hitchon C, Wong K, Ma G., et al. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002; 46:2587-97.
46. Hollander AP, Corke KP, Freemont A.J., et al. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001; 44:1540-4.
47. Suchting S, Eichmann A. Jagged gives endothelial tip cells an edge. Cell 2009; 137:988-90.
48. Chappell JC, Wiley DM, Bautch VL. Regulation of blood vessel sprouting. Semin Cell Dev Biol 2011; 22:1005-11.
49. Covey MV, Levison SW. Leukemia inhibitory factor participates in the expansion of neural stem/progenitors after perinatal hypoxia/ischemia. Neuroscience 2007; 148: 501-9.
50. Qiang L, Wu T, Zhang H.W., et al. HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 2011; 19:284-94.
51. Morga E, Mouad-Amazzal L, Felten P., et al. Jagged1 regulates the activation of astrocytes via modulation of NFkappaB and JAK/STAT/SOCS pathways. Glia 2009; 57:1741-53.
52. Daniel JM, Dutzmann J, Bielenberg W., et al. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 2012; 107:261.
53. Kong LY, Abou-Ghazal MK, Wei J., et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 2008; 14:5759-68.
54. Rosengren S, Corr M, Firestein G.S., et al. The JAK inhibitor CP-690, 550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2011; 71:440-7.
55. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 2011; 186:4234-43.
56. Garber K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 2013; 31:3-4.